Screener / SEC EDGAR /CIK 0001237831 /10-K filed Feb 24, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Globus Medical Inc GMED

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 2 above the last range given
Within the range 0 of 2 range targets
Below the range 0 below the last range given

The numbers GMED said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Diluted EPS (company-defined)
Fiscal 2026
Given $4.95 to $5.05 release Nov 5, 2026
– No standard number
The company's words
The Company reaffirms its full-year fiscal 2026 non-GAAP fully diluted EPS guidance to be in the range of $4.95 to $5.05, representing 24.4% to 26.9% growth over fiscal 2025 non-GAAP fully diluted EPS. release Nov 5, 2026
Revenue
Fiscal 2026
Given $3.18B to $3.22B release Jan 7, 2026
Kept $3.18B to $3.22B release Feb 24, 2026
Kept $3.18B to $3.22B release May 7, 2026
Kept $3.18B to $3.22B release Aug 6, 2026
– Not reported yet
The company's words
The Company established its full year 2026 revenue guidance range of $3.18 billion to $3.22 billion and fully diluted non-GAAP earnings per share range between $4.30 to $4.40. release Jan 7, 2026
The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.40 to $4.50 from the previous range of $4.30 to $4.40. release Feb 24, 2026
The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.70 to $4.80 from the previous range of $4.40 to $4.50. release May 7, 2026
The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.95 to $5.05 from the previous range of $4.70 to $4.80. release Aug 6, 2026
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $2.80B to $2.90B release Jul 21, 2025
$2.94B
10-K filed 2026-02-24
Above the range
The company's words
Looking ahead, we seek to continue this trend, while continuing to convert our Enabling Technologies pipeline.” 2025 Annual Guidance The Company reaffirms its guidance for full-year 2025 revenue to be in the range of $2.80 to $2.90 billion and its guidance for non-GAAP fully diluted earnings per share to be in the range of $3.00 to $3.30. release Jul 21, 2025
Revenue (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $2.80B to $2.90B release Aug 7, 2025
– No standard number
The company's words
Retrospectively, a s of January 1 , 202 4 , we no longer include acquisition of in-process research and development costs as an adjustment to non-GAAP Adjusted EBITDA or non-GAAP net income. 202 5 Annual Guidance The Company reaffirms its guidance for full-year 2025 revenue to be in the range of $2.80 to $2.90 billion and its guidance for non-GAAP fully diluted earnings per share to be in the range of $3.00 to $3.30 release Aug 7, 2025
Diluted EPS (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $2.68 to $2.70 release May 7, 2024
Lowered $2.00 release Nov 5, 2024
– No standard number
The company's words
This updated guidance is an increase over the prior full year 2024 revenue guidance of $2.450 to $2.475 billion, and non-GAAP fully diluted earnings per share guidance of $2.68 to $2.70. release May 7, 2024
As of September 30, 2024, we no longer include acquisition of in-process research and development as an adjustment to non-GAAP Adjusted EBITDA or non-GAAP net income. 202 4 Annual Guidance The Company raised its guidance for full year 2024 revenue to be in the range of $2.4 9 to $2. 5 0 billion, and non-GAAP fully diluted earnings per share to be in the range of $2. 9 0 to $ 3.00 release Nov 5, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $2.45B to $2.48B release Jan 10, 2024
Kept $2.45B to $2.48B release May 7, 2024
$2.52B
10-K filed 2025-02-20
Above the range
The company's words
The Company established its full year 2024 revenue guidance range of $2.450 billion to $2.475 billion and fully diluted non-GAAP earnings per share range between $2.68 to $2.70. release Jan 10, 2024
This updated guidance is an increase over the prior full year 2024 revenue guidance of $2.450 to $2.475 billion, and non-GAAP fully diluted earnings per share guidance of $2.68 to $2.70. release May 7, 2024
1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (16 releases since 2024-01-10), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GMED/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.